Generali Asset Management SPA SGR Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Generali Asset Management SPA SGR lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 18.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 290,157 shares of the biopharmaceutical company’s stock after acquiring an additional 44,727 shares during the period. Generali Asset Management SPA SGR’s holdings in Bristol Myers Squibb were worth $13,431,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at about $31,000. Trifecta Capital Advisors LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Accent Capital Management LLC purchased a new position in Bristol Myers Squibb in the 1st quarter worth approximately $33,000. CBIZ Investment Advisory Services LLC grew its position in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 231 shares in the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.6%

NYSE:BMY opened at $43.82 on Wednesday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $89.18 billion, a price-to-earnings ratio of 17.67, a price-to-earnings-growth ratio of 2.25 and a beta of 0.33. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The stock has a 50-day simple moving average of $46.18 and a 200 day simple moving average of $47.81.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on BMY shares. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday. Finally, Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $57.14.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.